Trial Profile
A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms STORM
- Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 14 Aug 2018 Results published in the Gut.
- 05 Jan 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.